DEA Rescheduling Won't Close Hemp-THC Loophole, Experts Warn

Rescheduling Preserves Hemp Definition Under 2018 Farm Bill

The proposed Schedule III classification doesn't amend the statutory definition of hemp, which remains anchored to delta-9 THC concentration on a dry-weight basis. The 2018 Farm Bill established that hemp contains no more than 0.3% delta-9 THC. That threshold excludes total THC, THCA, or post-decarboxylation measurements. DEA rescheduling addresses cannabis as a controlled substance but doesn't rewrite the Agricultural Improvement Act, leaving the hemp-marijuana distinction legally intact.

This creates a durable enforcement gap. Products with high THCA content—often 15% to 25% by weight—remain technically compliant if their delta-9 concentration stays below 0.3% at the point of sale. Upon heating, THCA decarboxylates into delta-9 THC at roughly 87% efficiency, delivering psychoactive potency indistinguishable from dispensary flower. The rescheduling proposal published in the Federal Register on May 16, 2024, made no reference to this conversion pathway or to total THC as an enforcement metric.

For full background on this story, see the CannIntel topic hub on DEA rescheduling.

FDA Authority Over Hemp Remains Narrow and Underutilized

The FDA retains jurisdiction over hemp-derived products marketed as food, dietary supplements, or drugs, but enforcement has been sparse and reactive. Between 2019 and 2025, the agency issued warning letters to 22 CBD and delta-8 THC manufacturers, primarily targeting unsubstantiated health claims rather than intoxicating potency. No federal rule currently limits THCA concentration in hemp flower. None restricts isomerization processes that convert CBD or delta-8 into delta-9 THC analogs.

The agency hasn't proposed a total-THC standard, leaving state regulators to draft their own testing protocols—many of which remain unenforced or inconsistent.

California, Colorado, and Oregon have adopted total-THC rules requiring post-decarboxylation testing, effectively reclassifying high-THCA hemp as marijuana. Texas and North Carolina enforce only the federal delta-9 standard, permitting THCA flower to circulate in smoke shops and online retail with minimal oversight. This patchwork creates compliance arbitrage: a product legal in one state can trigger felony possession charges across a state line.

Conversion Chemistry and Enforcement Blind Spots

Decarboxylation occurs predictably at temperatures above 105°C, converting THCA to delta-9 THC through loss of a carboxyl group. The reaction proceeds with 87% molar efficiency. A product with 20% THCA yields approximately 17.4% delta-9 THC when smoked or vaporized. Current federal testing protocols measure only pre-consumption cannabinoid profiles, a standard that ignores the product's intoxicating potential in its intended use case.

Chemical isomerization—converting CBD or delta-8 THC into delta-9 THC or analogs like THC-O and HHC—further complicates enforcement. These processes use acids, heat, or catalysts to rearrange molecular structure, producing compounds that may fall outside the Controlled Substances Act's definition of marijuana but deliver comparable psychoactive effects. The DEA hasn't issued guidance on whether synthetic or semi-synthetic cannabinoids derived from legal hemp precursors constitute controlled substances, and federal courts haven't yet ruled on the question.

What Rescheduling Changes—and What It Doesn't

Schedule III classification removes criminal penalties for possession and cultivation of cannabis under federal law, but doesn't legalize interstate commerce or resolve banking restrictions. Licensed state-legal operators will gain access to 280E tax relief, deducting ordinary business expenses previously disallowed under IRS code. The change also opens pathways for FDA-approved cannabis pharmaceuticals and permits federally funded research without DEA Schedule I protocols.

Hemp-derived intoxicating products remain in a separate legal category. They aren't rescheduled because they were never scheduled—the 2018 Farm Bill removed hemp from the CSA entirely. Rescheduling cannabis to Schedule III doesn't pull hemp back into the controlled-substance framework, nor does it authorize DEA enforcement against compliant hemp products. That authority remains with the FDA, which has shown limited appetite for aggressive regulation absent clear public-health signals.

Enforcement will vary. States with robust cannabis programs and total-THC testing will continue to treat high-THCA hemp as marijuana. States without such infrastructure will likely maintain the status quo, allowing THCA flower and converted cannabinoids to circulate through retail channels that bypass state cannabis licensing. The federal government hasn't signaled intent to harmonize these standards, leaving the delta-9 threshold as the operative legal line—for now.